GPD1L Enzyme Drives Liver Cancer Growth by Hijacking Fat Metabolism

This comprehensive study reveals how liver cancer cells hijack normal metabolism to fuel their aggressive growth. Researchers analyzed tissue samples from hepatocellular carcinoma (HCC) patients and found that the enzyme GPD1L was consistently overexpressed in tumors compared to healthy liver tissue, with 35% of patients showing more than 2-fold increases.

The team conducted extensive laboratory experiments using multiple HCC cell lines and mouse models to understand GPD1L's function. They discovered that GPD1L converts dihydroxyacetone phosphate (DHAP), a glucose breakdown product, into glycerol-3-phosphate (G3P), which then serves as a building block for triacylglycerol (fat) synthesis. This metabolic rewiring provides cancer cells with essential lipids needed for rapid growth and membrane formation.

Functional studies demonstrated that knocking down GPD1L significantly reduced cancer cell invasiveness, colony formation, and stemness properties. In mouse models, GPD1L knockdown inhibited both tumor growth and metastasis. Clinically, high GPD1L expression correlated with more frequent venous invasion (p=0.008) and significantly shorter overall survival (p=0.0017) in a cohort of 365 patients.

The researchers identified ELF1 as the key transcription factor driving GPD1L overexpression in cancer cells. When ELF1 levels were reduced, GPD1L expression decreased correspondingly, suggesting a direct regulatory relationship. Mass spectrometry confirmed that GPD1L facilitates the conversion of DHAP to G3P, while lipidomic analysis revealed its role in supporting triacylglycerol synthesis.

These findings highlight how cancer cells exploit normal metabolic pathways for malignant purposes and identify potential therapeutic targets. However, the study was conducted primarily in Asian populations and cell line models, requiring validation in diverse patient groups and clinical trials.